

## PRODUCT MONOGRAPH

**PR**TAMIFLU®

oseltamivir phosphate capsule

30 mg, 45 mg and 75 mg oseltamivir

oseltamivir phosphate powder for oral suspension

12 mg/mL oseltamivir when reconstituted

Antiviral Agent

Hoffmann-La Roche Limited  
2455 Meadowpine Boulevard  
Mississauga, Ontario  
L5N 6L7

Date of Preparation:  
December 22, 1999

Date of Revision:  
January 15, 2008

[www.rochecanada.com](http://www.rochecanada.com)

Submission Control No: 113996

Manufactured under license from Gilead Sciences Inc.  
® Trade-Mark of F. Hoffmann-La Roche AG, used under license  
© Copyright 1999-2007 by Hoffmann-La Roche Limited

CDS Version 3.0

## Table of Contents

<b>PART I: HEALTH PROFESSIONAL INFORMATION.....</b>	<b>3</b>
SUMMARY PRODUCT INFORMATION .....	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS .....	4
WARNINGS AND PRECAUTIONS.....	5
ADVERSE REACTIONS.....	7
DRUG INTERACTIONS .....	11
DOSAGE AND ADMINISTRATION.....	12
OVERDOSAGE .....	15
ACTION AND CLINICAL PHARMACOLOGY .....	15
STORAGE AND STABILITY.....	17
DOSAGE FORMS, COMPOSITION AND PACKAGING .....	17

**PR<sup>®</sup>TAMIFLU<sup>®</sup>**

Oseltamivir phosphate

**PART I: HEALTH PROFESSIONAL INFORMATION**

**SUMMARY PRODUCT INFORMATION**

<b>Route of Administration</b>	<b>Dosage Form / Strength</b>	<b>Clinically Relevant Nonmedicinal Ingredients</b>
Oral	Capsule / 30 mg, 45 mg and 75 mg oseltamivir	None <i>For a complete listing see Dosage Forms, Composition and Packaging section.</i>
Oral	Powder for Oral Suspension / 12 mg/mL oseltamivir when reconstituted	Sorbitol (see WARNINGS AND PRECAUTIONS) <i>For a complete listing see Dosage Forms, Composition and Packaging section.</i>

**INDICATIONS AND CLINICAL USE**

**Treatment of Influenza**

TAMIFLU (oseltamivir phosphate) is indicated for:

- The treatment of uncomplicated acute illness due to influenza infection in adults and adolescents (>13 years) who have been symptomatic for no more than 2 days.

The treatment indication is based on two Phase III clinical studies of naturally occurring influenza in adults in which the predominant infection was influenza A (95%) and a limited number with influenza B (3%) and influenza of unknown type (2%), reflecting the distribution of these strains in the community. The indication is also supported by influenza A and B challenge studies. No data are available to support the safety and efficacy of TAMIFLU in adult patients who commenced treatment after 40 hours of onset of symptoms.

- The treatment of uncomplicated acute illness due to influenza in pediatric patients 1 year and older who have been symptomatic for no more than 2 days.

The pediatric indication is based on one Phase III clinical study of naturally occurring influenza in pediatric patients aged 1 to 12 years in which 67% of influenza infected patients were infected with influenza A and 33% with influenza B.

TAMIFLU, when taken as recommended for the treatment of influenza, alleviates the symptoms and reduces their duration, (see CLINICAL TRIALS).

### **Prevention/Prophylaxis of Influenza**

The decision to administer TAMIFLU for prophylaxis to close contacts should be based on the knowledge that influenza is circulating in the area and the index case demonstrates characteristic symptoms of influenza. TAMIFLU is not effective in providing prophylaxis for respiratory infections other than influenza therefore a proper diagnosis of the index case is important.

TAMIFLU is not a substitute for influenza vaccination. Vaccination is the preferred method of prophylactic prevention against influenza. The use of TAMIFLU should not affect the evaluation of individuals for annual influenza vaccination, in accordance to “Health Canada. An Advisory Committee Statement on Influenza Vaccination for the Current Year/Season.”

The use of antivirals for the treatment and prevention of influenza should be determined on the basis of official recommendations taking into consideration variability of epidemiology and the impact of the disease in different geographical areas and patient populations.

TAMIFLU is indicated for:

- The prevention of influenza illness in adults and adolescents 13 years and older following close contact with an infected individual (the index case).

The prevention indication is based on a phase III clinical study programme consisting of 4 Phase III clinical trials.

- The prevention of influenza illness in pediatric patients 1 year and older following close contact with an infected individual (the index case).

This indication is based on a substudy of pediatric patients in a Phase III clinical trial.

### **CONTRAINDICATIONS**

- TAMIFLU (oseltamivir phosphate) is contraindicated in patients with known hypersensitivity to any of the components of the product. For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph.
- Use of TAMIFLU in children under 1 year of age is contraindicated. TAMIFLU may be safely administered only once the blood-brain barrier is fully developed (see TOXICOLOGY: Multiple Dose Toxicity)

## **WARNINGS AND PRECAUTIONS**

### **General**

No increased efficacy was demonstrated in adult subjects receiving 150 mg TAMIFLU (oseltamivir phosphate) twice daily for 5 days compared to those receiving 75 mg twice daily for the treatment of influenza.

There is no evidence for efficacy of TAMIFLU in any illness caused by agents other than influenza viruses Types A and B. Data on treatment of influenza B are limited.

Efficacy of TAMIFLU in patients who begin treatment after 48 hours of symptoms has not been established.

Efficacy of TAMIFLU in the treatment of subjects with chronic cardiac disease and/or respiratory disease has not been established. No difference in the incidence of complications was observed between the treatment and placebo groups in this population. No information is available regarding treatment of influenza in patients with any medical condition sufficiently severe or unstable to be considered at imminent risk of requiring hospitalization.

Safety and efficacy of repeated treatment or prevention courses have not been studied.

Efficacy of TAMIFLU for treatment or prevention of influenza in immunocompromised patients has not been established.

### **Endocrine and Metabolism**

A bottle of 30 g TAMIFLU powder for oral suspension contains 25.713 g of sorbitol. One dose of 45 mg oseltamivir administered twice daily delivers 2.6 g of sorbitol which is unsuitable for subjects with hereditary fructose intolerance.

### **Hepatic**

Cases of hepatotoxicity and elevated liver enzymes have been reported (see Post-Market Adverse Drug Reactions).

*Hepatic Impairment:* The safety, efficacy and pharmacokinetics in patients with hepatic impairment have not been established.

### **Neuropsychiatric**

There have been post-marketing reports (mostly from Japan) of self-injury and delirium with the use of TAMIFLU in patients with influenza. The reports were primarily among pediatric patients. The relative contribution of the drug to these events is not known. Patients with influenza should be closely monitored for signs of abnormal behaviour throughout the treatment with TAMIFLU, especially during the first few days.

### **Renal**

*Renal Impairment:* No dosing recommendation is available for patients undergoing routine hemodialysis and continuous peritoneal dialysis with end stage renal disease and for patients

with creatinine clearance  $\leq 10$  mL/min (see ACTION AND CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION: Dosage Adjustment).

### **Resistance**

The incidence of viral resistance in treatment study samples derived from post-treatment clinical isolates is 0.33% in the adults/adolescent population, and 4% in pediatric patients aged 1 to 12 years. The majority of the data are derived from subjects infected with H3N2 influenza A subtype and data from other subtypes are limited. The patients carrying resistant virus cleared the virus normally and showed no clinical deterioration. All resistant genotypes are disadvantaged compared to the corresponding wild-type isolate and are likely to be less contagious in man.

There has been no evidence for emergence of drug resistance associated with the use of TAMIFLU in clinical studies conducted to date in post-exposure (7 days), post-exposure within the household groups (10 days) and seasonal (42 days) prophylaxis of influenza (see MICROBIOLOGY: Resistance).

Insufficient information is available to fully characterize the risk of emergence of resistance to TAMIFLU in clinical use. (see MICROBIOLOGY: Resistance).

### **Skin and Hypersensitivity Reactions**

Severe skin and hypersensitivity reactions have been reported since marketing in patients treated with TAMIFLU (see Post-Market Adverse Reactions).

### **Special Populations**

**Pregnant Women:** At present, insufficient data are available in pregnant women taking TAMIFLU to enable an evaluation of the potential for TAMIFLU to cause fetal malformations or fetal toxicity. TAMIFLU should therefore be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Studies for effects on embryo-fetal development were conducted in rats (50, 250 and 1500 mg/kg/day) and rabbits (50, 150 and 500 mg/kg/day) by the oral route. Relative exposures at these doses were, respectively, 2, 13 and 100 times human exposure in the rat and 4, 8 and 50 times human exposure in the rabbit. Pharmacokinetic studies indicated that fetal exposure was seen in both species. In the rat study, minimal maternal toxicity was reported in the 1500 mg/kg/day group. In the rabbit study, slight and marked maternal toxicities were observed, respectively, in the 150 and 500 mg/kg/day groups. An increased incidence of abortion was seen in the 500 mg/kg/day group. There was a dose-dependent increase in the incidence rates of a variety of minor skeletal individual abnormalities and variants in the exposed offspring in these studies. However, the individual incidence rate of each skeletal abnormality or variant remained within the background rates of occurrence in the species studied. In view of the isolated nature of this finding it was considered to be of doubtful toxicological significance. For the results of administration of oseltamivir to juvenile rats see WARNINGS AND PRECAUTIONS, Nursing Women.

**Nursing Women:** It is not known whether oseltamivir or the active metabolite are excreted in human milk. In lactating rats, oseltamivir and the active metabolite are excreted in the milk. TAMIFLU should not be used by mothers who are nursing children under one year of age due to the potential risk to the nursing infant. Administration of oseltamivir to juvenile rats resulted in a high mortality rate along with high exposure to the brain. Oseltamivir may be safely administered only once the blood-brain barrier is fully developed (see TOXICOLOGY: Multiple Dose Toxicity).

**Pediatrics (< 1 year of age):** TAMIFLU should not be used in children under 1 year of age (see TOXICOLOGY: Multiple Dose Toxicity). The safety and efficacy of TAMIFLU in infants younger than 1 year of age have not been established (see CLINICAL TRIALS).

**Geriatrics (≥ 65 years of age):** Efficacy of TAMIFLU in the treatment of elderly patients has not been evaluated. Safety data in 372 elderly patients (≥65 years old) showed no overall difference between these subjects and younger adults. Based on drug exposure and tolerability, dosage adjustments are not anticipated for elderly patients (see ACTION AND CLINICAL PHARMACOLOGY: Special Populations and Conditions, Geriatrics).

Safety has been demonstrated in elderly residents of nursing homes who took TAMIFLU for the prevention of influenza. Many of these individuals had cardiac and/or respiratory disease, and most had received vaccine that season (see CLINICAL TRIALS).

## **ADVERSE REACTIONS**

### **Adverse Drug Reaction Overview**

In adult treatment studies with TAMIFLU (oseltamivir phosphate) the most frequently reported adverse events were nausea and vomiting. In the prevention studies adverse events were qualitatively very similar to those seen in the treatment studies. In the pediatric treatment and prophylaxis studies the most frequently reported adverse event was vomiting.

### **Clinical Trial Adverse Drug Reactions**

*Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

### **Adult Treatment Studies**

In a total of 2107 patients, including patients on placebo and 75 mg b.i.d. TAMIFLU, in adult phase III studies in the treatment of influenza, the most frequently reported adverse events were nausea and vomiting. These events were transient and generally occurred with first dosing. These events did not lead to patient discontinuation of study drug in the vast majority of instances. At the recommended dose of 75 mg twice daily, three patients withdrew because of nausea and the same number withdrew because of vomiting.

In adult phase III treatment studies, some adverse events occurred more frequently in patients taking TAMIFLU compared to those taking placebos. The adverse events that occurred the most frequently at the recommended dose, either for treatment or prophylaxis, are shown in Table 1. This summary includes healthy young adults and “at risk” patients (patients at higher risk of developing complications associated with influenza e.g. elderly patients and patients with chronic cardiac or respiratory disease). Those events with an incidence of  $\geq 1\%$  and which were reported more frequently in patients taking TAMIFLU compared with placebo, irrespective of causality, were nausea, vomiting, abdominal pain and headache.

**Table 1: Most Frequent Adverse Events in Studies in Naturally Acquired Influenza**

Adverse Event System Organ Class (MedDRA)	Treatment*		Prevention	
	TAMIFLU 75 mg twice daily for 5 days N=1057	Placebo N=1050	TAMIFLU 75 mg once daily N=1480	Placebo N=1434
<b>Ear and Labyrinth Disorders</b>				
Vertigo**	9 (0.9%)	6 (0.6%)	4 (0.3%)	3 (0.2%)
<b>Gastrointestinal Disorders</b>				
Nausea (without vomiting)	113 (10.7%)	71 (6.8%)	104 (7.0%)	56 (3.9%)
Vomiting	85 (8.0%)	32 (3.0%)	31 (2.1%)	15 (1.0%)
Diarrhea	58 (5.5%)	84 (8.0%)	48 (3.2%)	38 (2.6%)
Abdominal pain	23 (2.2%)	21 (2.0%)	30 (2.0%)	23 (1.6%)
<b>General Disorders and Administration Site Reactions</b>				
Fatigue**	8 (0.8%)	7 (0.7%)	117 (7.9%)	107 (7.5%)
<b>Infections and Infestations</b>				
Bronchitis	39 (3.7%)	52 (5.0%)	11 (0.7%)	17 (1.2%)
<b>Nervous System Disorders</b>				
Dizziness	20 (1.9%)	31 (3.0%)	24 (1.6%)	21 (1.5%)
Headache	17 (1.6%)	16 (1.5%)	298 (20.1%)	251 (17.5%)
Insomnia	11 (1.0%)	10 (1.0%)	18 (1.2%)	14 (1.0%)
<b>Respiratory, Thoracic and Mediastinal Disorders</b>				
Cough**	10 (0.9%)	12 (1.1%)	83 (5.6%)	86 (6.0%)

\* Adverse events included are all events reported the most frequently in the treatment studies in the oseltamivir 75 mg bid. Group, and events are ordered by decreasing incidence in that group.

\*\* These events no longer qualify as among the most-frequently recorded events for the treatment group but are included here for completeness as they were included in a previous version of this table which was based on a smaller dataset.

Additional adverse events occurring in <1% of patients receiving TAMIFLU for treatment included unstable angina, anemia, pseudomembranous colitis, humerus fracture, pneumonia, pyrexia, and peritonsillar abscess.

### **Adult Prevention Studies**

A total of 3434 subjects (adolescents, healthy adults and elderly) participated in 3 phase III prevention studies, of whom 1480 received the recommended dose of 75 mg once daily. Adverse events were qualitatively very similar to those seen in the treatment studies (see Table 1).

Additional adverse events  $\geq 1\%$  in the prevention studies included aches and pains, rhinorrhea, dyspepsia and upper respiratory tract infections. However, the difference in incidence between TAMIFLU and placebo for these events was less than 1%. There were no clinically relevant differences in the safety profile of the 942 elderly subjects who received TAMIFLU or placebo, compared with the younger population.

In a fourth study, an additional 399 subjects received 75 mg of TAMIFLU once daily for 10 days following the identification of a household index case. Similar to previous studies, nausea (8.3%), vomiting (4.5%), diarrhea (0.8%) and headache (7.8%) were among the most commonly reported adverse events.

### **Pediatric Treatment Studies**

A total of 1032 pediatric patients aged 1 to 12 years (including 698 otherwise healthy pediatric patients aged 1 to 12 and 334 asthmatic pediatric patients aged 6 to 12) participated in Phase III studies of TAMIFLU given for the treatment of influenza. A total of 515 pediatric patients received treatment with TAMIFLU oral suspension.

Adverse events occurring in  $> 1\%$  of pediatric patients receiving TAMIFLU are listed in Table 2. The most frequently reported adverse event was vomiting. Other events reported more frequently by pediatric patients treated with TAMIFLU included abdominal pain, epistaxis, ear disorder and conjunctivitis. These events generally occurred once and resolved despite continued dosing. They did not cause discontinuation of drug in the vast majority of cases.

Although otitis media, pneumonia, sinusitis and bronchitis were all reported in  $>1\%$  of pediatric patients receiving TAMIFLU, the incidence of these events in the group treated with TAMIFLU was lower than that in the placebo treated group.

The adverse event profile in adolescents is similar to that described for adult patients and pediatric patients aged 1 to 12 years.

**Table 2: Most Frequent Adverse Events Occurring in Children Aged 1 to 12 Years in Studies in Naturally Acquired Influenza**

Adverse Events System Organ Class (MedDRA)	Treatment <sup>a</sup>		Treatment <sup>b</sup>	Prophylaxis <sup>b</sup>
	TAMIFLU 2 mg/kg twice daily N= 515	Placebo N= 517	TAMIFLU Unit Dose <sup>c</sup> N=158	TAMIFLU Unit Dose <sup>c</sup> N=99
<b>Blood and Lymphatic system Disorders</b>				
Lymphadenopathy	5 (1.0%)	8 (1.5%)	1 (0.6%)	-
<b>Ear and Labyrinth Disorders</b>				
Ear disorder	9 (1.7%)	6 (1.2%)	-	-
Tympanic membrane disorder	5 (1.0%)	6 (1.2%)	-	-
<b>Eye Disorders</b>				
Conjunctivitis	5 (1.0%)	2 (0.4%)	-	-
<b>Gastrointestinal Disorders</b>				
Vomiting	77 (15.0%)	48 (9.3%)	31 (19.6%)	10 (10.1%)
Diarrhea	49 (9.5%)	55 (10.6%)	5 (3.2%)	1 (1.0%)
Abdominal pain	24 (4.7%)	20 (3.9%)	3 (1.9%)	3 (3.0%)
Nausea	17 (3.3%)	22 (4.3%)	10 (6.3%)	4 (4.0%)
<b>Infections and Infestations</b>				
Otitis media	45 (8.7%)	58 (11.2%)	2 (1.3%)	2 (2.0%)
Pneumonia	10 (1.9%)	17 (3.3%)	-	-
Sinusitis	9 (1.7%)	13 (2.5%)	-	-
Bronchitis	8 (1.6%)	11 (2.1%)	3 (1.9%)	-
<b>Respiratory, Thoracic and Mediastinal Disorders</b>				
Asthma (including aggravated)	18 (3.5%)	19 (3.7%)	-	1 (1.0%)
Epistaxis	16 (3.1%)	13 (2.5%)	2 (1.3%)	1 (1.0%)
<b>Skin and Subcutaneous Tissue Disorders</b>				
Dermatitis	5 (1.0%)	10 (1.9%)	1 (0.6%)	-

<sup>a</sup> Pooled data from Phase III trials of TAMIFLU treatment of naturally acquired influenza.

<sup>b</sup> Uncontrolled study comparing treatment (twice-daily dosing for 5 days) with prophylaxis (once-daily dosing for 10 days).

<sup>c</sup> Unit dose = age-based dosing (see DOSAGE AND ADMINISTRATION).

Adverse events included are: all events reported in the treatment studies with frequency  $\geq 1\%$  in the oseltamivir 75 mg bid group.

### **Pediatric Prevention Studies**

Pediatric patients aged 1 to 12 years participated in a post-exposure prophylaxis study in households, both as index cases (n=134) and as contacts (n=222). Gastrointestinal events were the most frequent, particularly vomiting. TAMIFLU was well tolerated in this study, the adverse events noted being consistent with those previously observed (see Table 2).

### **Post-Market Adverse Drug Reactions**

The following adverse reactions have been identified during post-marketing use of TAMIFLU. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to TAMIFLU exposure.

*Skin and hypersensitivity reactions:* rare cases of hypersensitivity reactions such as allergic skin reactions including dermatitis, rash, eczema, urticaria, and very rare cases of erythema multiforme, Stevens-Johnson-Syndrome and toxic epidermal necrolysis are reported. Also, allergy, anaphylactic/ anaphylactoid reactions and face edema are reported rarely.

*Liver and biliary system:* hepatotoxicity and elevated liver enzymes

*Neuropsychiatric events:* delirium or confusion, hallucinations, seizures, abnormal behaviour and depressed level of consciousness.

## **DRUG INTERACTIONS**

### **Overview**

Oseltamivir is extensively converted to oseltamivir carboxylate by esterases, located predominantly in the liver. Drug interactions involving competition for esterases have not been extensively reported in literature. Low protein binding of oseltamivir and oseltamivir carboxylate suggests that the probability of drug displacement interactions is low.

*In vitro* studies demonstrated that neither oseltamivir nor the active metabolite are good substrates for P450 mixed-function oxidases or for glucuronyl transferases.

### **Drug-Drug Interactions**

Cimetidine, a non-specific inhibitor of cytochrome P450 isoforms and competitor for renal tubular secretion of basic or cationic drugs, has no effect on plasma levels of oseltamivir or its active metabolite.

Clinically important drug interactions involving competition for renal tubular secretion are unlikely due to the known safety margin for most of these drugs, the elimination characteristics of the active metabolite (glomerular filtration and anionic tubular secretion) and the excretion capacity of these pathways. Co-administration of probenecid results in an approximate two-fold increase in exposure to the active metabolite due to a decrease in active anionic tubular secretion in the kidney. However, due to the wide safety margin of the active metabolite, no dose adjustments are required when co-administering with probenecid. Other drugs excreted via anionic tubular secretion have not been evaluated.

Co-administration with amoxicillin does not alter plasma levels of either compound, indicating that competition for the anionic secretion pathway is weak.

In six subjects, co-administration with acetaminophen did not alter plasma levels of oseltamivir, its active metabolite, or acetaminophen.

Co-administration with paracetamol does not alter plasma levels of oseltamivir, its active metabolite, or paracetamol.

No pharmacokinetic interactions between oseltamivir or its major metabolite have been observed when co-administering oseltamivir with paracetamol, acetyl-salicylic acid, cimetidine or with antacids (Magnesium and aluminum hydroxides and calcium carbonates).

In phase III treatment and prophylaxis clinical studies, TAMIFLU (oseltamivir phosphate) has been administered with commonly used drugs such as ACE inhibitors (enalapril, captopril), thiazide diuretics (bendrofluazide), antibiotics (penicillin), H<sub>2</sub>-receptor blockers (cimetidine), and analgesic agents (acetylsalicylic acid, ibuprofen and paracetamol). No change in adverse event profile or frequency has been observed as a result of co-administration of TAMIFLU with these compounds.

#### **Drug-Food Interactions**

Interactions with food have not been established.

#### **Drug-Herb Interactions**

Interactions with herbs have not been established.

#### **Drug-Laboratory Tests**

Interactions with laboratory tests have not been established.

### **DOSAGE AND ADMINISTRATION**

#### **Dosing Considerations**

**Hepatic Impairment:** The safety, efficacy and pharmacokinetics in patients with hepatic impairment have not been established.

**Infants:** The safety and efficacy of TAMIFLU (oseltamivir phosphate) in infants younger than 1 year of age have not been established. TAMIFLU should not be used in children under 1 year of age (see TOXICOLOGY: Multiple Dose Toxicity). Administration of TAMIFLU to infants younger than 1 year of age is contraindicated (see CONTRAINDICATIONS).

For information on renal impairment and elderly patients see Dosage Adjustment section.

### **Recommended Dose – Treatment of Influenza**

Treatment should begin no more than two days after the onset of symptoms of influenza.

**Adults and Adolescents (≥ 13 years):** The recommended oral dose of TAMIFLU capsules for the treatment of influenza in adults and adolescents 13 years and older is 75 mg twice daily, for 5 days.

**Pediatrics (1 to 12 years):** The recommended oral dose of TAMIFLU oral suspension for pediatric patients 1 year and older is shown in the table below. TAMIFLU oral suspension may also be used by adult patients who cannot swallow a capsule. For children old enough to safely swallow capsules, the 30 and 45 mg capsules can also be taken as outlined in the table below.

Body Weight in kg	Body Weight in lbs	Recommended Dose for 5 Days
≤15 kg	≤ 33 lbs	30 mg twice daily
> 15 kg to 23 kg	> 33 lbs to 51 lbs	45 mg twice daily
> 23 kg to 40 kg	> 51 lbs to 88 lbs	60 mg twice daily
> 40 kg	> 88 lbs	75 mg twice daily

An oral dosing dispenser with 30 mg, 45 mg, and 60 mg graduations is provided with the oral suspension; the 75 mg dose can be measured using a combination of 30 mg and 45 mg.

### **Recommended Dose – Prevention of Influenza**

Therapy should begin within 2 days of exposure after the onset of symptoms in the index case and continue for at least ten days. Viral shedding may continue for up to 14 days in children and elderly after the onset of influenza illness. Therefore, if the index case is a child or an elderly person, therapy with TAMIFLU for prevention may continue for up to 14 days.

Patients should be instructed to complete the entire course of therapy.

**Adults and adolescents (≥ 13 years):** The recommended oral dose of TAMIFLU for prevention of influenza following close contact with an infected individual (the index case) is 75 mg once daily.

**Pediatrics (1 to 12 years):** The recommended dose of TAMIFLU oral suspension for prevention in pediatric patients 1 year and older is shown in the table below. For children old enough to safely swallow capsules, the 30 and 45 mg capsules can also be taken as outlined in the table below.

Body Weight in kg	Body Weight in lbs	Recommended Dose for at least 10 Days
≤15 kg	≤ 33 lbs	30 mg once daily
> 15 kg to 23 kg	> 33 lbs to 51 lbs	45 mg once daily
> 23 kg to 40 kg	> 51 lbs to 88 lbs	60 mg once daily
> 40 kg	> 88 lbs	75 mg once daily

An oral dosing dispenser with 30 mg, 45 mg, and 60 mg graduations is provided with the oral suspension; the 75 mg dose can be measured using a combination of 30 mg and 45 mg.

### **Dosage Adjustment**

**Renal Impairment:** No dose adjustment is necessary for patients with creatinine clearance above 30 mL/min.

No dosing recommendation is available for patients undergoing routine hemodialysis and continuous peritoneal dialysis with end stage renal disease and for patients with creatinine clearance ≤ 10 mL/min (see ACTION AND CLINICAL PHARMACOLOGY: Special Populations and Conditions, Renal Insufficiency).

*Treatment of Influenza:* In patients with a creatinine clearance of 10 - 30 mL/min, it is recommended that the dose be reduced to 75 mg of TAMIFLU once daily for 5 days.

*Prevention of influenza:* In patients with a creatinine clearance of 10 - 30 mL/min, it is recommended that the dose be reduced to 75 mg of TAMIFLU every other day, or alternatively, one 30 mg capsule or 30 mg suspension once daily.

**Elderly Patients:** No dose adjustment is required for elderly patients (See WARNINGS AND PRECAUTIONS: Special Populations, Geriatrics).

### **Missed Dose**

The missed dose should be taken as soon as remembered, then the regular dosing schedule should be continued. Two doses of TAMIFLU should not be taken at the same time.

### **Administration**

TAMIFLU may be taken with or without food (see ACTION AND CLINICAL PHARMACOLOGY: Pharmacokinetics, Absorption). However, taking with food may enhance tolerability in some patients.

## **Reconstitution of Oral Suspension:**

It is recommended that TAMIFLU powder for oral suspension be reconstituted by the pharmacist prior to dispensing to the patient.

1. Tap the closed bottle several times to loosen the powder.
2. Measure 52 mL of water in a graduated cylinder.
3. Add the total amount of water for reconstitution to the bottle and shake the closed bottle well for 15 seconds.
4. Remove the child-resistant cap and push bottle adapter into neck of bottle.
5. Close bottle with child-resistant cap tightly. This will assure the proper seating of the bottle adapter in the bottle and child-resistant status of the cap.

Dispense with patient information leaflet and oral dispenser. It is recommended to write the date of expiration of the reconstituted suspension on the bottle label. (The shelf life of the reconstituted suspension is 10 days).

A bottle of 30 g TAMIFLU powder for oral suspension contains 25.713 g of sorbitol. One dose of 45 mg oseltamivir administered twice daily delivers 2.6 g of sorbitol which is unsuitable for subjects with hereditary fructose intolerance (see WARNINGS AND PRECAUTIONS: Endocrine and Metabolism).

**Note: Shake the TAMIFLU oral suspension well before each use.**

## **OVERDOSAGE**

At present there has been no experience with overdose. Single doses of up to 1000 mg of TAMIFLU (oseltamivir phosphate) have been associated with nausea and/or vomiting.

## **ACTION AND CLINICAL PHARMACOLOGY**

### **Mechanism of Action**

TAMIFLU (oseltamivir phosphate) is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active metabolite, oseltamivir carboxylate. The active metabolite is a selective inhibitor of influenza virus neuraminidase enzymes which are glycoproteins found on the virion surface. Viral neuraminidase is important both for viral entry into uninfected cells and for the release of recently formed virus particles from infected cells and the further spread of infectious virus in the body. The proposed mechanism of action of oseltamivir is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release.

Oseltamivir is readily absorbed after oral administration and converted by hepatic esterases to its active metabolite. The mean volume of distribution ( $V_{ss}$ ) of the active metabolite is approximately 23 L. The active metabolite is not further metabolized and is eliminated in the urine. The half-life of elimination of this metabolite is 6 to 10 hours. Renal clearance (18.8 L/h) exceeds glomerular filtration rate (7.5 L/h), indicating that tubular secretion in addition to glomerular filtration occurs. The prodrug which reaches the systemic circulation (less than 5%)

is eliminated by renal excretion also. The binding of oseltamivir to human plasma protein is 42% and that of the active metabolite is negligible, approximately 3%.

Exposure to the active metabolite is inversely proportional to declining renal function.

### **Pharmacokinetics**

**Absorption:** Oseltamivir is readily absorbed from the gastrointestinal tract after oral administration of TAMIFLU and is extensively converted predominantly by hepatic esterases to the active metabolite. At least 75% of an oral dose reaches the systemic circulation as the active metabolite. Exposure to the prodrug is less than 5% relative to the active metabolite. Plasma concentrations of active metabolite are proportional to dose and are not significantly affected by co-administration with food (see DOSAGE AND ADMINISTRATION).

**Distribution:** The mean volume of distribution ( $V_{SS}$ ) of the active metabolite is approximately 23 litres in humans.

The binding of oseltamivir to human plasma protein is 42% and that of the active metabolite is negligible, approximately 3%.

**Metabolism:** Oseltamivir is extensively converted to the active metabolite by esterases located predominantly in the liver. Neither oseltamivir nor the active metabolite are substrates for, or inhibitors of, cytochrome P450 isoforms.

**Excretion:** Absorbed oseltamivir is primarily (>90%) eliminated by conversion to the active metabolite. The active metabolite is not further metabolized and is eliminated in the urine. Peak plasma concentrations of the active metabolite decline with a half-life of 6 to 10 hours in most subjects. The active drug is eliminated entirely (>99%) by renal excretion. Renal clearance (18.8 L/h) exceeds glomerular filtration rate (7.5 L/h), indicating that tubular secretion in addition to glomerular filtration occurs. Less than 20% of an oral radiolabelled dose is eliminated in feces.

### **Special Populations and Conditions**

**Pediatrics:** The pharmacokinetics of oseltamivir have been evaluated in single dose pharmacokinetic studies in pediatric patients aged 1 to 16 years. Multiple dose pharmacokinetics were studied in a small number of pediatric patients aged 3-12 years enrolled in a clinical trial. Younger pediatric patients cleared both the prodrug and the active metabolite faster than adults resulting in lower exposure for a given mg/kg dose. Doses of 2 mg/kg give oseltamivir carboxylate exposures comparable to those achieved in adults receiving a single 75 mg capsule dose (approximately 1 mg/kg). The pharmacokinetics of oseltamivir in pediatric patients over 12 years of age are similar to those in adults.

TAMIFLU should not be used in children under 1 year of age (see TOXICOLOGY: Multiple Dose Toxicity).

**Geriatrics:** Exposure to the active metabolite at steady-state was 25% to 35% higher in elderly patients (age range 65 to 78) compared to young adults given comparable doses of TAMIFLU. Half-lives observed in the elderly patients were similar to those seen in young adults. On the basis of drug exposure and tolerability, dosage adjustments are not required for elderly patients for either treatment or prevention (see DOSAGE AND ADMINISTRATION: Dosage Adjustment).

**Hepatic Insufficiency:** The safety, efficacy and pharmacokinetics in patients with hepatic impairment have not been established.

**Renal Insufficiency:** Administration of 100 mg of TAMIFLU twice daily for five days to patients with various degrees of renal impairment showed that exposure to the active metabolite is inversely proportional to declining renal function.

No dosing recommendation is available for patients undergoing routine hemodialysis and continuous peritoneal dialysis with end stage renal disease and for patients with creatinine clearance  $\leq$  10 mL/min.

Treatment of Influenza: In patients with a creatinine clearance of 10 - 30 mL/min, it is recommended that the dose be reduced to 75 mg of TAMIFLU once daily for 5 days.

Prevention of influenza: In patients with a creatinine clearance of 10 - 30 mL/min, it is recommended that the dose be reduced to 75 mg of TAMIFLU every other day or 30 mg suspension every day (See DOSAGE AND ADMINISTRATION: Dosage Adjustment).

## **STORAGE AND STABILITY**

TAMIFLU (oseltamivir phosphate) Capsules: Store at 15 to 30°C.

TAMIFLU Powder for Oral Suspension: Store dry powder at 15 to 25°C. Store reconstituted suspension in a refrigerator at 2 to 8°C. Do not freeze. Discard unused portion 10 days after reconstitution.

## **DOSAGE FORMS, COMPOSITION AND PACKAGING**

### **TAMIFLU (oseltamivir phosphate) 30 mg, 45 mg and 75 mg Capsules**

#### **Composition**

TAMIFLU (oseltamivir phosphate) is available as capsules containing 30 mg, 45 mg or 75 mg oseltamivir for oral use in the form of oseltamivir phosphate. In addition to the active ingredient, each capsule contains corn starch, croscarmellose sodium, povidone K30, sodium stearyl fumarate and talc. The 30 mg capsule shell contains gelatin, red iron oxide, yellow iron oxide and titanium dioxide. The 45 mg capsule shell contains gelatin, black iron oxide and titanium dioxide. The 75 mg capsule shell contains gelatin, black iron oxide, red iron oxide, yellow iron oxide and titanium dioxide. Each capsule is printed with blue ink, which includes FD&C Blue No. 2 as a colorant.

**Availability**

TAMIFLU 30 mg capsules are available as light yellow hard gelatin capsules. "ROCHE" is printed in blue ink on the light yellow body and "30 mg" is printed in blue ink on the light yellow cap.

TAMIFLU 45 mg capsules are available as grey hard gelatin capsules. "ROCHE" is printed in blue ink on the grey body and "45 mg" is printed in blue ink on the grey cap.

TAMIFLU 75 mg capsules are available as grey/light yellow hard gelatin capsules. "ROCHE" is printed in blue ink on the grey body and "75 mg" is printed in blue ink on the light yellow cap.

All three capsules strengths are available in blister packages of 10.

**TAMIFLU Powder for Oral Suspension****Composition**

TAMIFLU powder for oral suspension contains 900 mg oseltamivir as oseltamivir phosphate per bottle, which when reconstituted contains 12 mg/mL oseltamivir. The nonmedicinal ingredients are: monosodium citrate, saccharin sodium, sodium benzoate, sorbitol, titanium dioxide, tutti-frutti flavoring and xanthan gum.

**Availability**

TAMIFLU powder for oral suspension is available as a white powder blend for reconstitution to a white tutti-frutti-flavored suspension. Available in 100 mL glass bottles with a bottle adapter and 1 oral dispenser \*. Net contents after reconstitution: 75 mL containing oseltamivir phosphate equivalent to 900 mg oseltamivir base.

\*Oral dosing dispenser manufactured by F. Hoffmann-La Roche Ltd., 4070 Basel, Switzerland.